February 25, 2016 (Shareholders Foundation) - An investigation on behalf of investors of PTC Therapeutics, Inc. (NASDAQ:PTCT) shares over potential securities laws violations by PTC Therapeutics and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of PTC Therapeutics, Inc. (NASDAQ:PTCT) concerning whether a series of statements by PTC Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) grew from $15.07 per share in May 2014 to as high as $73.27 per share in March 2015.

On February 23, 2016, PTC Therapeutics, Inc. announced that it received a Refuse to File letter from the United States Food and Drug Administration (FDA) regarding PTC Therapeutics' New Drug Application (NDA) for Translarna (ataluren), an oral, first-in-class, protein restoration therapy for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) declined to as low as $10.11 per share.